FR15C0048I2 - IL-17 ANTAGONIST ANTIBODIES - Google Patents

IL-17 ANTAGONIST ANTIBODIES

Info

Publication number
FR15C0048I2
FR15C0048I2 FR15C0048C FR15C0048C FR15C0048I2 FR 15C0048 I2 FR15C0048 I2 FR 15C0048I2 FR 15C0048 C FR15C0048 C FR 15C0048C FR 15C0048 C FR15C0048 C FR 15C0048C FR 15C0048 I2 FR15C0048 I2 FR 15C0048I2
Authority
FR
France
Prior art keywords
antagonist antibodies
antagonist
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0048C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0048(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of FR15C0048I1 publication Critical patent/FR15C0048I1/en
Application granted granted Critical
Publication of FR15C0048I2 publication Critical patent/FR15C0048I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
FR15C0048C 2004-08-05 2015-07-03 IL-17 ANTAGONIST ANTIBODIES Active FR15C0048I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (2)

Publication Number Publication Date
FR15C0048I1 FR15C0048I1 (en) 2015-08-28
FR15C0048I2 true FR15C0048I2 (en) 2015-11-20

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0048C Active FR15C0048I2 (en) 2004-08-05 2015-07-03 IL-17 ANTAGONIST ANTIBODIES

Country Status (39)

Country Link
US (8) US7807155B2 (en)
EP (5) EP2364729B3 (en)
JP (1) JP4682200B2 (en)
KR (2) KR100852523B1 (en)
CN (1) CN101001645B (en)
AR (1) AR050200A1 (en)
AT (1) ATE517924T1 (en)
AU (2) AU2005268857C1 (en)
BR (3) BRPI0513078C1 (en)
CA (1) CA2573586C (en)
CY (6) CY1111963T1 (en)
DK (4) DK2366405T3 (en)
EC (1) ECSP077198A (en)
ES (4) ES2487533T7 (en)
FR (1) FR15C0048I2 (en)
GB (1) GB0417487D0 (en)
HK (3) HK1101277A1 (en)
HR (3) HRP20110758T4 (en)
HU (4) HUE038187T2 (en)
IL (1) IL180717A (en)
LT (3) LT2902039T (en)
LU (2) LU92768I2 (en)
MA (1) MA28982B1 (en)
MX (1) MX2007001338A (en)
MY (1) MY144925A (en)
NL (1) NL300749I2 (en)
NO (9) NO336279B1 (en)
NZ (1) NZ552658A (en)
PE (1) PE20060418A1 (en)
PL (4) PL2902039T3 (en)
PT (4) PT2364729E (en)
RU (2) RU2426741C3 (en)
SG (1) SG155186A1 (en)
SI (4) SI2364729T1 (en)
TN (1) TNSN07034A1 (en)
TR (1) TR201808057T4 (en)
TW (1) TWI359153B (en)
WO (1) WO2006013107A1 (en)
ZA (1) ZA200700242B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101296706B (en) * 2005-09-01 2011-11-30 先灵公司 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
DK1963368T6 (en) * 2005-12-13 2020-06-29 Lilly Co Eli Anti-IL-17 ANTIBODIES
LT2913343T (en) 2005-12-20 2018-11-26 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
AR060017A1 (en) 2006-01-13 2008-05-21 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR DICKKOPF -1 ANTIBODIES
KR20080099290A (en) * 2006-01-31 2008-11-12 노파르티스 아게 Il-17 antagonistic antibodies for treating cancer
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
ES2373069T3 (en) * 2006-08-11 2012-01-31 Schering Corporation ANTIBODIES FOR IL-17A.
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (en) 2007-02-12 2014-02-21 Merck Sharp & Dohme Use of il-23 antagonists for treatment of infection
MX2009009167A (en) 2007-02-28 2009-09-04 Schering Corp Combination therapy for treatment of immune disorders.
EP4177268A3 (en) 2007-05-29 2023-05-24 Novartis AG New indications for anti-il-1beta therapy
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
JP2010534664A (en) * 2007-07-23 2010-11-11 セントコア・オーソ・バイオテツク・インコーポレーテツド Methods and compositions for treatment of fibrosis related diseases using IL-17 antagonists
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
KR101616995B1 (en) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US9309313B2 (en) * 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US9353180B2 (en) * 2008-04-29 2016-05-31 Amgen Research (Munich) Gmbh Method of treatment by the administration of inhibitors of GM-CSF and IL-17
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
BRPI0908312A2 (en) 2008-05-05 2015-08-18 Novimmune Sa '' Isolated fully human monoclonal antibody, pharmaceutical composition, symptom-relieving method of a clinical indication, and method of relieving a symptom of an autoimmune disease, inflammatory disorder or cell proliferation disorder ''
CN102112494A (en) 2008-06-03 2011-06-29 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
WO2009149189A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BRPI0915448A2 (en) 2008-07-08 2015-11-10 Abbott Lab prostaglandin e2 double variable domain immunoglobulins and uses thereof
UA103499C2 (en) * 2008-09-29 2013-10-25 Рош Глікарт Аг Antibody against human il17 and uses thereof
TWI541021B (en) 2009-03-05 2016-07-11 艾伯維有限公司 Il-17 binding proteins
MY153078A (en) * 2009-04-27 2014-12-31 Novartis Ag Compositions and methods for increasing muscle growth
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
JP2013503607A (en) 2009-09-01 2013-02-04 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
RU2012119756A (en) 2009-10-15 2013-11-20 Эбботт Лэборетриз IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP5922025B2 (en) 2009-10-30 2016-05-25 ヤンセン バイオテツク，インコーポレーテツド IL-17A antagonist
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013537414A (en) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Antibodies against IL-17
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012027570A2 (en) 2010-08-26 2012-03-01 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
PT3590949T (en) 2010-10-01 2022-08-02 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
PL2625199T3 (en) * 2010-10-08 2018-04-30 Novartis Ag Methods of treating psoriasis using il-17 antagonists
KR20180129991A (en) * 2010-11-05 2018-12-05 노파르티스 아게 Methods of treating rheumatoid arthritis using il-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
TW201307845A (en) 2010-12-13 2013-02-16 Novartis Ag Predictive methods and methods of treating arthritis using IL-17 antagonists
JP5947041B2 (en) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 Safe IL-17 production inhibitor
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
US8580265B2 (en) 2011-01-14 2013-11-12 Ucb Pharma S.A. Antibody molecules which bind IL-17A and IL-17F
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
WO2012135415A1 (en) * 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2856252A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP2015508994A (en) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins against IL-13 and / or IL-17
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP3505176A1 (en) 2012-04-02 2019-07-03 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EA201401077A1 (en) 2012-04-05 2015-02-27 Ф.Хоффманн-Ля Рош Аг BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
MX2014012640A (en) 2012-04-20 2015-01-15 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists.
EP3456741B1 (en) 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
EP2914625A2 (en) 2012-11-01 2015-09-09 AbbVie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
AU2014213599C1 (en) 2013-02-08 2017-09-07 Novartis Ag Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (en) * 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
JP2016536327A (en) 2013-08-30 2016-11-24 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Antibody neutralizing GM-CSF in the treatment of rheumatoid arthritis or for use as an analgesic
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3072905B1 (en) 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
WO2015113494A1 (en) * 2014-01-28 2015-08-06 北京韩美药品有限公司 Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
JP2017528465A (en) 2014-09-10 2017-09-28 ノバルティス アーゲー Use of an IL-17 antagonist to inhibit the progression of structural damage in patients with psoriatic arthritis
RU2609627C2 (en) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
PE20171067A1 (en) 2014-10-14 2017-07-24 Novartis Ag ANTIBODY MOLECULES BINDING AND USES OF PD-L1
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
AR103172A1 (en) * 2014-12-22 2017-04-19 Novartis Ag SELECTIVE REDUCTION OF CYSTEINE WASTE IN ANTIBODIES IL-17
NZ732978A (en) 2015-01-12 2022-01-28 Affibody Ab Il-17a-binding polypeptides
CN107407677B (en) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 Gene expression markers and treatment of multiple sclerosis
CN108251431B (en) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 Double-carrier system and application thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
MX2018000694A (en) 2015-07-16 2018-05-07 Lilly Co Eli Treatment of pruritus.
ES2878188T3 (en) 2015-07-29 2021-11-18 Novartis Ag Combination therapies comprising antibody molecules against LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
MX2018007423A (en) 2015-12-17 2018-11-09 Novartis Ag Antibody molecules to pd-1 and uses thereof.
BR112018067951A2 (en) 2016-03-10 2019-02-05 Viela Bio Inc ilt7-binding molecules and methods of using these
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
RU2680011C2 (en) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Trispecific il-17a, il-17f and other proinflammatory molecules antibodies
FR3051673B1 (en) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris INHIBITORS OF THE INTERLEUKIN 17 PATHWAY FOR THE TREATMENT OF CHRONIC DISEASES DUE TO HPV
CN107488227A (en) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 Anti-human IL-17 A monoclonal antibodies, its preparation method and application
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
BR112019004990A2 (en) 2016-09-14 2019-06-04 Beijing hanmi pharm co ltd antibody that specifically binds to il-17a and functional fragment thereof
JP2019505516A (en) 2016-11-28 2019-02-28 ノバルティス アーゲー Method of treating acne using an interleukin-17 (IL-17) antagonist
CN110494453B (en) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 Anti-tryptase antibodies, compositions thereof and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10676522B2 (en) 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
CN108359011B (en) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 Target the antibody, preparation method and application of interleukin-17 A
CN111344043A (en) 2017-11-02 2020-06-26 诺华股份有限公司 Methods of treating tendinopathy using interleukin-17 (IL-17) antagonists
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
TW201925782A (en) 2017-11-30 2019-07-01 瑞士商諾華公司 BCMA-targeting chimeric antigen receptor, and uses thereof
JP2021519589A (en) * 2018-03-29 2021-08-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ Treatment of autoimmune and inflammatory disorders with antibodies that bind to interleukin 17A (IL-17A)
TW202016136A (en) 2018-06-01 2020-05-01 瑞士商諾華公司 Binding molecules against bcma and uses thereof
CN112513078B (en) * 2018-07-31 2022-11-18 沈为群 anti-IL-17A antibodies and uses thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
JP2022523908A (en) 2019-01-31 2022-04-27 ヌマブ セラピューティクス アクチェンゲゼルシャフト Multispecific antibodies with specificity for TNFα and IL-17A, antibodies targeting IL-17A, and how to use them.
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (en) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 A kind of stable Su Jin monoclonal antibody injection and preparation method thereof
CA3142267A1 (en) 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (en) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 Feed supplement culture medium for CHO cell culture and preparation method and application thereof
AU2020322569A1 (en) 2019-07-26 2022-02-17 Sinocelltech Ltd Humanized anti-IL17A antibody and use thereof
WO2021018191A1 (en) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Method for treating autoimmune disease by il-17 antagonist
CN114981302A (en) 2019-09-20 2022-08-30 诺华股份有限公司 Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
CA3156167A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with large molecule modulators
US20230009657A1 (en) 2019-11-19 2023-01-12 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
AU2020396455A1 (en) 2019-12-06 2022-06-02 Novartis Ag Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists
CN111040035B (en) * 2019-12-31 2022-05-24 南京融捷康生物科技有限公司 Antibody aiming at IL-17RA protein and preparation method and application thereof
BR112022026273A2 (en) 2020-06-23 2023-01-17 Novartis Ag METHODS OF TREATMENT OF OCULAR THYROID DISEASE AND GRAVES ORBITOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
UY39484A (en) 2020-11-02 2022-06-30 Novartis Ag INTERLEUKIN-17 INHIBITORS
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
CA3202877A1 (en) 2020-12-02 2022-06-09 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
US20220251502A1 (en) 2020-12-22 2022-08-11 Novartis Ag Methods for reducing the oxidation level of cysteine residues in a secreted recombinantly-expressed protein during cell culture
WO2023209519A1 (en) 2022-04-25 2023-11-02 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
DK0817847T4 (en) * 1995-03-23 2009-10-05 Immunex Corp IL-17 receptor
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
JP3253633B2 (en) 1995-10-27 2002-02-04 シェーリング コーポレイション Novel use of mammalian CTLA-8 and related drugs
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
CA2309604C (en) 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
PT1076703E (en) 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
CA2343569C (en) 1998-09-17 2010-09-14 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (en) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd Therapeutic agent for and diagnosis of chronic rheumatism and
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (en) 1998-11-16 1999-04-08 Reutter Werner Prof Dr Med Recombinant glycoproteins and medicinal products containing them
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP1141297B1 (en) 1999-01-11 2009-09-30 Schering Corporation Interleukin-17 related mammalian cytokines. polynucleotides encoding them . uses
AR022237A1 (en) 1999-01-11 2002-09-04 Schering Corp PURIFIED MAMMARY CYTOKINS; REAGENTS AND RELATED METHODS
ATE216875T1 (en) 1999-01-27 2002-05-15 Idea Ag NON-INVASIVE VACCINATION THROUGH THE SKIN
WO2000047228A1 (en) 1999-02-12 2000-08-17 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (en) * 1999-09-09 2001-03-30 Nec Corp Portable telephone system with camera
PT2275449T (en) 2000-06-16 2016-12-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002033083A2 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
CA2425506A1 (en) 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
CA2435151A1 (en) 2001-01-25 2002-12-27 Zymogenetics, Inc. Method for treating psoriasis
ATE374214T1 (en) * 2001-04-27 2007-10-15 Kirin Brewery MONOCLONAL ANTI-CD-40 ANTIBODY
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
AU2004270103B2 (en) * 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
WO2005108616A1 (en) 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101296706B (en) 2005-09-01 2011-11-30 先灵公司 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
ES2487533T3 (en) 2014-08-21
CY2018027I2 (en) 2020-05-29
HRP20110758T4 (en) 2015-07-31
PL2364729T6 (en) 2016-06-30
CA2573586A1 (en) 2006-02-09
RU2426741C2 (en) 2011-08-20
EP2902039B1 (en) 2018-04-11
SI1776142T1 (en) 2011-11-30
ATE517924T1 (en) 2011-08-15
NO20151787L (en) 2006-02-06
CN101001645B (en) 2012-09-05
KR20070036166A (en) 2007-04-02
PL2366405T3 (en) 2015-08-31
CY2018027I1 (en) 2020-05-29
EP2902039A1 (en) 2015-08-05
US20230235038A1 (en) 2023-07-27
CA2573586C (en) 2013-06-25
PT1776142E (en) 2011-10-06
ES2536228T3 (en) 2015-05-21
US10344084B2 (en) 2019-07-09
CY1120723T1 (en) 2019-12-11
HK1101277A1 (en) 2007-10-12
TR201808057T4 (en) 2018-06-21
LTPA2015029I1 (en) 2022-07-11
DK2902039T3 (en) 2018-07-16
AU2005268857C1 (en) 2012-01-19
SI2366405T1 (en) 2015-07-31
RU2426741C3 (en) 2017-11-15
CY1116256T1 (en) 2017-02-08
NO2022026I1 (en) 2022-06-24
RU2007108067A (en) 2008-09-10
NL300749I2 (en) 2017-11-02
EP1776142B3 (en) 2015-06-24
MY144925A (en) 2011-11-30
JP4682200B2 (en) 2011-05-11
ES2487533T7 (en) 2015-07-14
AU2010201689A1 (en) 2010-05-20
PL2902039T3 (en) 2018-09-28
AU2005268857B8 (en) 2010-05-27
US8119131B2 (en) 2012-02-21
EP1776142B9 (en) 2016-09-07
ES2367440T3 (en) 2011-11-03
BRPI0513078A (en) 2008-04-22
US20100215666A1 (en) 2010-08-26
US8617552B2 (en) 2013-12-31
NO20171697A1 (en) 2007-03-30
NZ552658A (en) 2009-11-27
NO2015023I1 (en) 2015-11-02
TW200617025A (en) 2006-06-01
ES2367440T7 (en) 2015-07-14
DK2364729T6 (en) 2015-07-06
ES2677245T3 (en) 2018-07-31
DK2364729T3 (en) 2014-07-21
PE20060418A1 (en) 2006-06-15
PL2364729T3 (en) 2014-10-31
LTC1776142I2 (en) 2022-07-11
NO2016017I1 (en) 2016-08-23
EP2366405B1 (en) 2015-02-25
NO337286B1 (en) 2016-02-29
NO20150064L (en) 2007-03-30
AU2010201689B2 (en) 2011-09-29
HUE025815T2 (en) 2016-04-28
NO337129B1 (en) 2016-01-25
US20120107325A1 (en) 2012-05-03
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
PL1776142T6 (en) 2016-06-30
BR122017009404B1 (en) 2022-02-22
NO20070985L (en) 2007-03-30
CY2015030I2 (en) 2017-11-14
EP2364729A3 (en) 2012-01-18
US20140079719A1 (en) 2014-03-20
HUS1800040I1 (en) 2018-11-28
HK1207559A1 (en) 2016-02-05
BR122018075556B1 (en) 2022-10-18
NO2018007I1 (en) 2018-02-14
BRPI0513078B8 (en) 2019-08-27
EP2364729A2 (en) 2011-09-14
PL1776142T3 (en) 2011-12-30
IL180717A0 (en) 2007-06-03
HRP20150480T1 (en) 2015-07-17
RU2011113153A (en) 2012-10-20
JP2008507988A (en) 2008-03-21
CN101001645A (en) 2007-07-18
GB0417487D0 (en) 2004-09-08
SI2902039T1 (en) 2018-07-31
EP1776142B1 (en) 2011-07-27
US7807155B2 (en) 2010-10-05
NO341384B1 (en) 2017-10-30
ECSP077198A (en) 2007-02-28
IL180717A (en) 2012-07-31
ZA200700242B (en) 2008-08-27
LUC00088I2 (en) 2018-12-17
US20190270804A1 (en) 2019-09-05
KR20080029018A (en) 2008-04-02
CY1115444T1 (en) 2017-01-04
HUE038187T2 (en) 2018-10-29
TNSN07034A1 (en) 2008-06-02
EP2366405A2 (en) 2011-09-21
HUS1500037I1 (en) 2017-10-30
LU92768I2 (en) 2015-11-03
FR15C0048I1 (en) 2015-08-28
AU2005268857B2 (en) 2010-01-28
BRPI0513078B1 (en) 2019-02-19
CY1111963T1 (en) 2015-11-04
HRP20110758T1 (en) 2011-11-30
KR100852523B1 (en) 2008-08-14
LTPA2018515I1 (en) 2018-10-25
HK1256639A1 (en) 2019-09-27
US20090280131A1 (en) 2009-11-12
LT2902039T (en) 2018-06-25
NO2015023I2 (en) 2015-10-26
SI2364729T1 (en) 2014-08-29
PT2366405E (en) 2015-06-30
HRP20181069T1 (en) 2018-09-07
EP3409288A1 (en) 2018-12-05
AR050200A1 (en) 2006-10-04
TWI359153B (en) 2012-03-01
AU2005268857A1 (en) 2006-02-09
DK1776142T3 (en) 2011-10-31
MA28982B1 (en) 2007-11-01
EP2364729B1 (en) 2014-05-14
EP1776142A1 (en) 2007-04-25
ES2367440T9 (en) 2021-04-28
MX2007001338A (en) 2008-03-11
BRPI0513078C1 (en) 2021-05-25
PT2364729E (en) 2014-09-01
NO336279B1 (en) 2015-07-06
EP2366405A3 (en) 2012-01-18
DK1776142T6 (en) 2015-07-06
CY2015030I1 (en) 2015-11-04
WO2006013107A1 (en) 2006-02-09
NO20150065L (en) 2007-03-30
PL1776142T4 (en) 2018-04-30
US20170355762A1 (en) 2017-12-14
DK2366405T3 (en) 2015-05-11
EP2364729B3 (en) 2015-06-24
PT2902039T (en) 2018-07-17
SG155186A1 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
FR15C0048I2 (en) IL-17 ANTAGONIST ANTIBODIES
CY2016030I1 (en) ANTIBODIES AGAINST IL-17
NO20071430L (en) Anti-OX4OL antibodies
MA29014B1 (en) ANTIBODY FORMULATIONS
NO20076607L (en) TWEAK - binding antibody
DK1964852T3 (en) ANTI-ILT7 ANTIBODY
DE602005027428D1 (en) toner
DK1599504T3 (en) Modified antibody
DK1809978T3 (en) MODULE-SHOOTING RANGE
NO20071069L (en) Anti-CD154 antibody
DE602005012636D1 (en) TION
DE602004019389D1 (en) toner
DE602005017454D1 (en) SILICON CONNECTION
DK1809660T3 (en) THYMUS-SPECIFIC PROTEIN
DE602004025215D1 (en) Probe
DE602005020180D1 (en) IMPROVED MEASUREMENT SYSTEM
DE502005000300D1 (en) probe
FI20041538A0 (en) goniometer
FR2880112B1 (en) WEIGHER
FR2877833B1 (en) CORRECTEUR OF LORDOSES
DE112005003066A5 (en) Geodetic device
FR2871542B3 (en) SPHERICAL SOUPAGE
DE602005013453D1 (en) throttle
UA10990S (en) CUP
ES1058615Y (en) EXHIBITOR-MATTRESS TESTER